Tumor microenvironment and therapy最新文献

{"title":"A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.","authors":"C. Portlock, P. Hamlin, J. Gerecitano, A. Noy, M. Palomba, Janelle Walkley, S. Corcoran, Jocelyn C. Migliacci, H. Schoder, G. Papanicolaou, A. Markowitz","doi":"10.1515/TUMOR-2015-0001","DOIUrl":"https://doi.org/10.1515/TUMOR-2015-0001","url":null,"abstract":"BACKGROUND\u0000We have prospectively studied a three month course of clarithromycin (substituted by Prevpac®, lansoprazole/ amoxicillin/ clarithromycin, in the first two wks when stool H pylori+) for non-bulky, advanced stage indolent lymphoma. These patients are often candidates for expectant monitoring and it is during this period that a window of opportunity may exist to identify and treat associated infections.\u0000\u0000\u0000METHODS\u0000All previously untreated patients with a new diagnosis of indolent lymphoma (FL and non-FL) meeting GELF criteria were treated with 12 weeks of clarithromycin. There were 32 evaluable patients, 4 of whom had stool H pylori.\u0000\u0000\u0000RESULTS\u0000At one month post-antibiotic therapy, we have observed lymphoma responses in 7 of 32 patients (21.9%). Two additional patients had objective response during followup (28.1% overall response). The median treatment free survival for antibiotic responders is 69.9 months and for non-responders, 30.6 months (p = 0.019).\u0000\u0000\u0000CONCLUSION\u0000Three response patterns have been noted, perhaps suggestive of an immune-mediated response -- prompt PET negative; flair with delayed PET negative response; and gradual continuous improvement. This prospective study appears promising, may be a step toward developing a lymphoma prevention strategy by reducing \"antigen drive,\" and deserves further clinical/biological study. http://clinicaltrials.gov/show/NCT00461084.","PeriodicalId":90757,"journal":{"name":"Tumor microenvironment and therapy","volume":"2 1 1","pages":"14-18"},"PeriodicalIF":0.0,"publicationDate":"2015-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/TUMOR-2015-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67482315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors.","authors":"Cameron J Koch, W Timothy Jenkins, Kevin W Jenkins, Xiang Yang Yang, A Lee Shuman, Stephen Pickup, Caitlyn R Riehl, Ramesh Paudyal, Harish Poptani, Sydney M Evans","doi":"10.2478/tumor-2012-0001","DOIUrl":"10.2478/tumor-2012-0001","url":null,"abstract":"<p><p>Classical descriptions of tumor physiology suggest two origins for tumor hypoxia; steady-state (diffusion-limited) hypoxia and cycling (perfusion-modulated) hypoxia. Both origins, primarily studied and characterized in murine models, predict relatively small, isolated foci or thin shells of hypoxic tissue interspersed with contrasting oxic tissue. These foci or shells would not be expected to scale with overall tumor size since the oxygen diffusion distance (determined by oxygen permeability and tissue oxygen consumption rate) is not known to vary dramatically from tumor to tumor. We have identified much larger (macroscopic) regions of hypoxia in rat gliosarcoma tumors and in larger human tumors (notably sarcomas and high-grade glial tumors), as indicated by biochemical binding of the hypoxia marker, EF5. Thus, we considered an alternative cause of tumor hypoxia related to a phenomenon first observed in window-chamber tumor models: namely longitudinal arteriole gradients. Although longitudinal arteriole gradients, as originally described, are also microscopic in nature, it is possible for them to scale with tumor size if tumor blood flow is organized in an appropriate manner. In this organization, inflowing blood would arise from relatively well-oxygenated sources and would branch and then coalesce to poorly-oxygenated outflowing blood over distances much larger than the length of conventional arterioles (multi-millimeter scale). This novel concept differs from the common characterization of tumor blood flow as disorganized and/or chaotic. The organization of blood flow to produce extended longitudinal gradients and macroscopic regional hypoxia has many important implications for the imaging, therapy and biological properties of tumors. Herein, we report the first experimental evidence for such blood flow, using rat 9L gliosarcoma tumors grown on the epigastric artery/vein pair.</p>","PeriodicalId":90757,"journal":{"name":"Tumor microenvironment and therapy","volume":"1 ","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247177/pdf/nihms573822.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32847831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}